ReviewFrontiers in pediatrics2022
An Update on Childhood-Onset Takayasu Arteritis.
Review in Frontiers in pediatrics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- A Systematic Review of Anti-TNF and Anti-IL-6 Treatments for Pediatric Takayasu Arteritis: Addressing a Therapeutic Dilemma.Paediatric drugs · 2025Pooled it
- Real-World Biomarkers for Pediatric Takayasu Arteritis.International journal of molecular sciences · 2024Pooled it
- Cutaneous Pediatric Vasculitis: A Clinico-Histopathological Overview of Common and Novel Entities.Dermatopathology (Basel, Switzerland) · 2026Review
- Neurological Complications in Pediatric Takayasu Arteritis: Insights from a Single-Center Experience.Journal of clinical medicine · 2026Article
- Patency of Distal Aortic Occlusion Treated With DCBs in a 13-Year-Old Child With TA.JACC. Case reports · 2026Article
- Refractory Kawasaki Disease in Infants Complicated with Giant Coronary Artery Aneurysms and Takayasu Arteritis: A Rare Case Report and Literature Review.Vascular health and risk management · 2026Review
- Beyond clinical criteria: emerging biomarkers and advanced imaging in the diagnosis, monitoring and treatment of vasculitides.Frontiers in medicine · 2026Review
- FDG-PET/MR in paediatric pyrexia of unknown origin: early detection of Takayasu arteritis-a single-centre experience.Frontiers in pediatrics · 2026Article
- Advances in the pathophysiology, diagnosis and treatment of Takayasu arteritis.Nature reviews. Rheumatology · 2025Review
- Expert consensus on the off-label use of drugs for pediatric rare diseases in China (2025 edition).Translational pediatrics · 2025Review
- New avenues in childhood vasculitis.Pediatric rheumatology online journal · 2025Review
- Childhood-onset Takayasu arteritis: clinical presentation, challenges and disease course.Pediatric rheumatology online journal · 2025Article
- Childhood-Onset Takayasu Arteritis: Clinical Features of Disease and Relapse Risk Factors.Children (Basel, Switzerland) · 2025Article
- Diverse Vascular Manifestations of Takayasu Arteritis: Coronary Artery Stenosis and Aneurysmal Dilation in pediatric patients.Clinical medicine insights. Arthritis and musculoskeletal disorders · 2025Article
- A challenging case of Takayasu's arteritis in a young male with various manifestations and poor outcome.BMC cardiovascular disorders · 2024Article
- Vasculitis in Children.Turkish archives of pediatrics · 2024Review
- Article
- A retrospective study of infantile-onset Takayasu arteritis: experience from a tertiary referral center in China.Frontiers in cardiovascular medicine · 2024Article
- Cardiac involvement and cardiovascular risk factors in pediatric primary systemic vasculitides.Clinical rheumatology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Takayasu Arteritis (TAK) is a rare large vessel vasculitis affecting the aorta and its major branches. The heterogeneous and often severe clinical manifestations result from systemic and local inflammation as well as end-organ ischemia. Disease flares are common and contribute to accrued damage over time with significant morbidity and mortality. Newer understanding of the pathogenesis in TAK has paved the way for the use of pathway targeting agents such as tumor necrosis factor (TNF)α- or interleuking (IL)-6-inhibitors with improved disease control. Nevertheless, long-term data are lacking, particularly in children; prognosis often remains guarded and the disease burden high. This article aims at providing a comprehensive review of childhood-onset TAK with a focus on recent publications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.